A Phase 2/3 interventional study of Carvedilol and Endoscopic band ligation in Esophageal Varices, sponsored by Sherief Abd-Elsalam. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-05.
Sponsored by Sherief Abd-Elsalam · Phase 2/3, Interventional, and Prevention
Among 11 studies testing carvedilol in Esophageal and Gastric Varices — 1 open to participants now, 2 under way, 1 of them phase 3. Carvedilol · Esophageal and Gastric Varices.
Among the 11 studies testing carvedilol in Esophageal and Gastric Varices, this one is the 5th largest by planned enrollment, is one of 2 that started in 2018, is the only one in phase 2/3, and was the 9th registered.
150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.
This study's planned enrollment of 306 is above the median of 110 across 96 interventional studies indexed under Esophageal and Gastric Varices.
Browse Esophageal and Gastric Varices studies →1 of the 11 studies testing carvedilol in Esophageal and Gastric Varices is open now, in 1 country. Each count lists the studies.
Carvedilol: first FDA approval 1995 (COREG). What it is approved for, and how studies give it, is on its page →
Of the 19 Esophageal and Gastric Varices studies recruiting now, 12 (63%) set no upper age limit and 1 (5%) stop at 75 or younger; 1 take children under 18; 1 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2018.
Median enrollment 240 across the 11 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
None of the 11 has an industry lead sponsor. The 8 most frequent:
Sherief Abd-Elsalam is the lead sponsor of 50 studies on the registry; 23 are open to participants now.
Sherief Abd-Elsalam has 2 studies filed under Esophageal and Gastric Varices — fewer than ten, so there is no comparison to draw.
1 of the studies testing carvedilol in Esophageal and Gastric Varices that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05872698King's College Hospital NHS TrustBeta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial. | 2026-12 |
Among the 11 studies testing carvedilol in Esophageal and Gastric Varices, from their registry updates:
Nothing recorded among them since 2026-09-25.
Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension
A Randomized controlled trial of carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aged >18 years
Exclusion Criteria:
History of variceal bleeding or previous primary prevention of varices.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carvedilol
Drug: Carvedilol
Band Ligation
Procedure: Endoscopic band ligation
Carvedilol
Also known as: carvid
Endoscopic band ligation
Also known as: band ligation
Number of patients with the first variceal bleeding within 1 year
The number of patients with the first variceal bleeding within 1 year
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2018 (actual). Primary completion is estimated for Dec 2030, 146 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carvedilol
Esophageal and Gastric Varices →
Sherief Abd-Elsalam